Literature DB >> 16944335

No evidence for angiotensin type 2 receptor gene polymorphism in intron 1 in patients with coarctation of the aorta and Ullrich-Turner syndrome.

E Struwe1, K Krammer, J Dötsch, M Metzler, H G Dörr, R Cesnjevar, W Rascher, A Koch.   

Abstract

In male patients with congenital anomalies of the kidney and urinary tract, an increased incidence of a polymorphism in the angiotensin type 2 receptor gene (AT2R) has been identified. The AT2R has been shown to be involved in apoptosis, particularly during embryogenesis. The aim of this study was to examine the A-->1675G transition polymorphism in intron 1 of the AT2R gene that is located on the X chromosome in patients with coarctation of the aorta (CoA) with and without Ullrich-Turner syndrome (UTS). Screening of DNA samples was performed with restriction fragment length polymorphism analysis. Ninety-seven patients with CoA, 28 girls with UTS, 10 girls with UTS and CoA, and 96 control individuals were studied. There was no significant difference in the distribution of A and G-genotypes in any of the patient groups compared to controls. An A-->1675G transition in the AT2R gene seems not to be involved in the pathogenesis of aortic coarctation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944335     DOI: 10.1007/s00246-005-1049-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  25 in total

1.  Developmental expression of renal angiotensin II receptor genes in the mouse.

Authors:  J Kakuchi; T Ichiki; S Kiyama; B L Hogan; A Fogo; T Inagami; I Ichikawa
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

Review 2.  Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.

Authors:  Tianhua Niu; Xiu Chen; Xiping Xu
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome.

Authors:  H Nagashima; Y Sakomura; Y Aoka; K Uto; M Ogawa; S Aomi; H Koyanagi; N Ishizuka; M Naruse; M Kawana; H Kasanuki
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

Review 4.  Turner's syndrome.

Authors:  M B Ranke; P Saenger
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

5.  The effects of angiotensin II and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns.

Authors:  R L Price; W Carver; D G Simpson; L Fu; J Zhao; T K Borg; L Terracio
Journal:  Dev Biol       Date:  1997-12-15       Impact factor: 3.582

6.  Angiotensin type II receptor expression and ureteral budding.

Authors:  K Oshima; Y Miyazaki; J W Brock; M C Adams; I Ichikawa; J C Pope
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

Review 7.  Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations.

Authors:  Bruno Baudin
Journal:  Pharmacogenomics       Date:  2002-01       Impact factor: 2.533

8.  Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats.

Authors:  S Otsuka; M Sugano; N Makino; S Sawada; T Hata; Y Niho
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190

9.  Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts.

Authors:  J J Lopez; B H Lorell; J R Ingelfinger; E O Weinberg; H Schunkert; D Diamant; S S Tang
Journal:  Am J Physiol       Date:  1994-08

10.  The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells.

Authors:  M Stoll; U M Steckelings; M Paul; S P Bottari; R Metzger; T Unger
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  1 in total

Review 1.  [Turner syndrome and genetic polymorphism: a systematic review].

Authors:  Alessandra Bernadete Trovó de Marqui
Journal:  Rev Paul Pediatr       Date:  2015-02-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.